EC Number   |
Inhibitors |
Structure |
|---|
    1.14.14.14 | (E)-2,4-dimethoxy-N-(4-(phenyldiazenyl)phenyl)benzenesulfonamide |
not effective on HFF-1 cells |
 |
| 1.14.14.14 | (E)-4-cyano-N-(4-(phenyldiazenyl)phenyl)benzenesulfonamide |
not effective on HFF-1 cells |
|
| 1.14.14.14 | (E)-N-((1H-benzo[d]imidazole-2-yl)methyl)-2,4-dimethoxy-N-(4-(phenyldiazenyl)phenyl)benzenesulfonamide |
treatment induces a dose-dependent increase of the percentage of cells found in the apoptotic stage, compound shows an anti-proliferative effect on MCF-7 cells, being blocked in the G1/S phase checkpoint. Compound is not effective on HFF-1 cells |
|
| 1.14.14.14 | 1,4,6-androstatriene-3,17-dione |
treatment with the aromatase inhibitor ATD results in significantly decreased aromatase activity in male and female brain,but has no significant impact on ovarian aromatase activity |
  |
| 1.14.14.14 | 1-(3-bromo-4-methoxybenzene-1-sulfonyl)-3-[(1H-imidazol-1-yl)methyl]piperidine |
- |
|
| 1.14.14.14 | 1-[3-(2-chloro-6-nitrophenyl)benzene-1-sulfonyl]-3-[(1H-imidazol-1-yl)methyl]piperidine |
- |
|
| 1.14.14.14 | 17beta,11alpha-dihydroxy-17alpha-methylandrosta-2-oxa-4-ene-3-one |
- |
|
| 1.14.14.14 | 19-hydroxyandrost-4-ene-3,17-dione |
competitive with substrates androst-4-ene-3,17-dione and 19-oxoandrost-4-ene-3,17-dione |
|
| 1.14.14.14 | 19-hydroxyandrost-4-ene-3,17-dione |
competitively inhibits the formation of 19-hydroxyandrost-4-ene-3,17-dione and estrogen |
|
| 1.14.14.14 | 19-nortestosterone |
competitive inhibitor of both aromatization and cytochrome P450 binding of androst-4-ene-3,17-dione |
|
